FindTrial
Sign In

Vosaroxin

DRUG8 trials

Sponsors

Sunesis Pharmaceuticals, M.D. Anderson Cancer Center, Washington University School of Medicine, Weill Medical College of Cornell University, University Hospital, Angers

Conditions

Acute DiseaseAcute Myeloid LeukemiaAcute Myeloid Leukemia (AML)Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia With Multilineage DysplasiaLeukemiaLeukemia, Lymphocytic, AcuteLeukemia, Myeloid, Chronic

Phase 1

Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
CompletedNCT00246662
Sunesis PharmaceuticalsLeukemia, Lymphocytic, Acute, Leukemia, Myeloid, Chronic, Leukemia, Nonlymphocytic, Acute +1
Start: 2005-11-14End: 2009-04-30Updated: 2017-03-30
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
CompletedNCT01893320
M.D. Anderson Cancer CenterLeukemia
Start: 2013-07-18End: 2021-01-11Updated: 2022-02-09
Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
CompletedNCT01913951
Washington University School of MedicineMyelodysplastic Syndromes
Start: 2013-11-22End: 2024-04-29Updated: 2024-05-02
Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy
CompletedNCT01980056
Weill Medical College of Cornell UniversityMyelodysplastic Syndrome
Start: 2013-10-25End: 2015-01-19Updated: 2019-02-19

Phase 2

Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia
CompletedNCT00607997
Sunesis PharmaceuticalsAcute Disease, Acute Myeloid Leukemia, Leukemia +2
Start: 2008-05-15End: 2009-11-23Updated: 2017-06-28
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
RecruitingNCT02416388
University Hospital, AngersAcute Myeloid Leukemia (AML)
Start: 2015-01-31End: 2032-01-31Target: 3100Updated: 2024-08-07
Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia
CompletedNCT02658487
Vanderbilt-Ingram Cancer CenterAcute Myeloid Leukemia (AML), Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Multilineage Dysplasia +4
Start: 2016-03-31End: 2024-09-30Updated: 2025-04-15
Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
CompletedNCT03338348
University of UlmAcute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)
Start: 2018-04-19End: 2019-10-31Updated: 2020-10-28

Related Papers

Impact of midostaurin in younger AML patients intensively treated with high-dose anthracycline
Blood2025-11-03
Frequency and impact of FLT3-ITD microclones in younger AML patients
Blood2025-11-03
Intermediate-Dose Cytarabine as Postinduction AML Therapy
NEJM Evidence2025-06-244 citations
Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network
Blood2024-11-054 citations
Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
Blood2024-11-05
Cyclosporine <i>Versus</i> Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
Blood2024-11-05
Hyperleukocytosis Increases the Risk of Early Relapses Independently of Genetics in AML
Blood2023-11-021 citations
The VITAL Trial: Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of acute Myeloid Leukemia
Blood2019-11-1311 citations
Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
Haematologica2017-07-2013 citations
<scp>REVEAL</scp>‐1, a phase 2 dose regimen optimization study of vosaroxin in older poor‐risk patients with previously untreated acute myeloid leukaemia
British Journal of Haematology2014-11-1730 citations
Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Journal of Clinical Oncology2014-05-201 citations